A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.
A study is set to explore if artificial intelligence (AI) can help doctors make better decisions when it comes to treating prostate cancer. While prostate cancer diagnosis has become safer and more ...
California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...
A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...
A study is set to explore if artificial intelligence (AI) can help doctors make better decisions when it comes to treating prostate cancer. While prostate cancer diagnosis has become safer and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results